These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 22575753)
1. Effect of expansion chamber geometry on atomization and spray dispersion characters of a flashing mixture containing inerts. Part I. Numerical predictions and dual laser measurements. Ju D; Shrimpton J; Bowdrey M; Hearn A Int J Pharm; 2012 Aug; 432(1-2):23-31. PubMed ID: 22575753 [TBL] [Abstract][Full Text] [Related]
2. Effect of expansion chamber geometry on atomization and spray dispersion characters of a flashing mixture containing inerts. Part II: High speed imaging measurements. Ju D; Shrimpton J; Bowdrey M; Hearn A Int J Pharm; 2012 Aug; 432(1-2):32-41. PubMed ID: 22579579 [TBL] [Abstract][Full Text] [Related]
3. The effect of reduction of propellant mass fraction on the injection profile of metered dose inhalers. Ju D; Shrimpton J; Hearn A Int J Pharm; 2010 May; 391(1-2):221-9. PubMed ID: 20227471 [TBL] [Abstract][Full Text] [Related]
4. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Sheth P; Stein SW; Myrdal PB Int J Pharm; 2013 Oct; 455(1-2):57-65. PubMed ID: 23911912 [TBL] [Abstract][Full Text] [Related]
5. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. Dunbar CA; Watkins AP; Miller JF J Aerosol Med; 1997; 10(4):351-68. PubMed ID: 10175964 [TBL] [Abstract][Full Text] [Related]
6. Drug distribution transients in solution and suspension-based pressurised metered dose inhaler sprays. Duke DJ; Scott HN; Kusangaya AJ; Kastengren AL; Matusik K; Young P; Lewis D; Honnery D Int J Pharm; 2019 Jul; 566():463-475. PubMed ID: 31173800 [TBL] [Abstract][Full Text] [Related]
7. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology. Kleinstreuer C; Shi H; Zhang Z J Aerosol Med; 2007; 20(3):294-309. PubMed ID: 17894536 [TBL] [Abstract][Full Text] [Related]
8. Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Williams RO; Patel AM; Barron MK; Rogers TL Drug Dev Ind Pharm; 2001 May; 27(5):401-12. PubMed ID: 11448047 [TBL] [Abstract][Full Text] [Related]
9. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Williams RO; Repka M; Liu J Drug Dev Ind Pharm; 1998 Aug; 24(8):763-70. PubMed ID: 9876524 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002 [TBL] [Abstract][Full Text] [Related]
11. Plume temperature emitted from metered dose inhalers. Brambilla G; Church T; Lewis D; Meakin B Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465 [TBL] [Abstract][Full Text] [Related]
12. Influence of metering chamber volume and water level on the emitted dose of a suspension-based pMDI containing propellant 134a. Williams RO; Liu J; Koleng JJ Pharm Res; 1997 Apr; 14(4):438-43. PubMed ID: 9144728 [TBL] [Abstract][Full Text] [Related]
13. Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. Mason-Smith N; Duke DJ; Kastengren AL; Stewart PJ; Traini D; Young PM; Chen Y; Lewis DA; Soria J; Edgington-Mitchell D; Honnery D Pharm Res; 2016 May; 33(5):1249-58. PubMed ID: 26887680 [TBL] [Abstract][Full Text] [Related]
14. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. Cheng YS; Fu CS; Yazzie D; Zhou Y J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related]
16. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Zhu B; Traini D; Chan HK; Young PM Drug Dev Ind Pharm; 2013 Nov; 39(11):1625-37. PubMed ID: 24087854 [TBL] [Abstract][Full Text] [Related]
17. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants. Dickinson PA; Seville PC; McHale H; Perkins NC; Taylor G J Aerosol Med; 2000; 13(3):179-86. PubMed ID: 11066021 [TBL] [Abstract][Full Text] [Related]